Pancreas, Phase II
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alexis Walker
- Alison Johnson
- Andrea Brennan
- Armand Russo, MD
- Brooke Chaves
- David Witt, MD
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jade Vanacore
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Jose Morales-Marin
- Justin Persico, MD
- Katelyn Scott
- Kathleen Fenn, MD
- Kayla Martello
- Kristen Hoxie
- Laura Van Metre Baum, MD, MPH
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Osarugue Otasowie
- Pamela L. Kunz, MD
- Pawan Karanam, MD
- Renee Moye
- Sara Anastasio, RN
- Stacey Stein, MD
- Teresa White
- Vanna Dest
- Virginia Syombathy
- Zia Rahman, MD
- Last Updated04/18/2024
- Study HIC#2000034823